Skip to content
type1.science

Sernova Cell Pouch Bio-hybrid Organ

Sernova Biotherapeutics Inc. (iPSC islets with Evotec SE; tegoprubart with Eledon Pharmaceuticals; conformal coating with University of Miami / Dr. Alice Tomei)

Islets that last for years — and drugs that last just as long.

A pocket-sized, retrievable scaffold implanted under the abdominal skin and left to grow blood vessels, then loaded with donor islets — giving transplanted cells a vascularized home instead of the liver. In an ongoing Phase 1/2 trial it has kept islets alive and functioning for years, with 8 of 12 patients insulin-independent on interim sponsor-reported data. It is a scaffold, not an immune shield: recipients take standard lifelong anti-rejection drugs, exactly as they would for any donor-islet transplant. Sernova also holds a preclinical per-islet "conformal coating" that is meant to remove those drugs one day — it has never been in a human.

Years awayEarly evidenceencapsulationscaffoldisletdeviceretrievabledonor-isletconformal-coatingOfficial site ↗

The scorecard

Immunosuppression-free20

No advantage here today. The trial protocol starts systemic immunosuppression before the islets go in and keeps the patient on it — a standard chronic anti-rejection regimen, the same burden as any donor-islet transplant. The planned Cohort C swaps tacrolimus for tegoprubart (anti-CD40L), which Sernova itself calls an immunosuppressive agent: calcineurin-free is not drug-free. The per-islet coating that would actually remove the drugs is preclinical and scored nowhere here.

Insulin independence60

Genuine human results: 8 of 12 patients insulin-independent on interim data, the first sustained beyond four years. Discounted because the data are interim, single-arm, sponsor-reported and not peer-reviewed, and because some patients also received a portal-vein islet "top-up", so not all of the effect belongs to the pouch.

Durability55

The strongest durability evidence of any islet-containing device: living, vascularized islets making insulin, glucagon and somatostatin were recovered from an explanted pouch more than five years after transplant, with no harmful fibrosis. But that graft survived under continuous immunosuppression, and n is small.

Low invasiveness45

A multi-step surgical course: four pouches implanted under the abdominal sheath, islets loaded about six weeks later, a second transplant if needed, and possibly a portal-vein top-up. Retrievability is a real safety advantage over liver infusion — the graft can be removed and examined — but this is more surgery, not less.

Eligibility breadth25

Narrow. Adults 18–65 with hypoglycemia unawareness and severe hypos, BMI ≤30, no prior transplant — and, because it uses a deceased-donor pancreas and requires chronic immunosuppression, it is gated by both organ scarcity and fitness to take the drugs.

Maturity35

Active Phase 1/2 (NCT03513939, n=17), closed to enrolment, completing October 2026. No peer-reviewed efficacy data yet. The confirmatory Cohort C has slipped to H2 2026 and is explicitly contingent on funding Sernova does not have — the company disclosed going-concern doubt in June 2026.

The full picture

Sernova's Cell Pouch is a small, non-degradable scaffold implanted just under the skin of the abdomen and left alone for a few weeks so the body grows blood vessels into it. Only then are donor islets loaded into the now-prevascularized chambers, giving the cells an oxygen-rich home instead of the liver — where many infused islets die and the graft can never be biopsied or removed.12 It works: this is the most durable islet graft anyone has shown in a device.

What it does not do is free anyone from anti-rejection drugs.

The immunosuppression question, answered plainly

The Cell Pouch is a scaffold, not an immune shield. The trial protocol is explicit — immunosuppression is started before the islets are transplanted and optimized over about three weeks, so the patient is stable on the drugs by the time the cells go in.1 Recipients then stay on a standard chronic anti-rejection regimen, the same burden carried by any donor-islet transplant recipient.12 Nothing about the pouch changes that.

The planned Cohort C does change the drug, not the fact of the drug: tacrolimus is replaced by tegoprubart (AT-1501), Eledon's investigational anti-CD40L antibody.34 The rationale is sound — tacrolimus is diabetogenic and directly toxic to the islets it is meant to protect.3 But tegoprubart is chronic systemic immunosuppression, and Sernova's own filings call it exactly that: "Eledon's immunosuppressive agent".3 Calcineurin-free is not drug-free. Anyone reading Cohort C as a step toward an immunosuppression-free product is reading it wrong.

Key results so far

In the first cohort of 6 patients (8-channel pouch), all 6 reached sustained insulin independence, the first patient for more than four years, with HbA1c in the non-diabetic range.5 When one pouch was explanted more than five years after transplant, it held abundant, well-vascularized islets making insulin, glucagon and somatostatin, with no harmful scarring5 — the single most impressive durability result in this field. A May 2025 interim update across both cohorts (12 patients) reported 8 of 12 insulin-independent, 9 of 12 with HbA1c below 7.0%, and 7 of 12 with restored C-peptide (≥0.3 ng/mL); Sernova reconfirmed those figures in its June 2026 filing.36

Read them with the caveats attached: interim, single-arm, non-randomized, reported by the device's maker, and not peer-reviewed. Some patients also received a portal-vein islet "top-up" on top of the pouch,3 so the pouch does not own all of the benefit.

The conformal coating — preclinical, and quieter than it used to be

Sernova has a genuinely interesting per-islet immune-protection technology: a thin, cross-linked PEG hydrogel wrapped snugly around each islet, selectively permeable so glucose, oxygen and insulin pass while antibodies and immune cells are blocked.7 Because the gel hugs each islet instead of bundling hundreds into one big capsule, the coated cluster stays small enough to survive in a vascularized site — the classic fix for the oxygen-starvation problem that killed earlier encapsulation devices.78

The evidence is preclinical, and thinner than the headline suggests. The much-cited "over 100 days without immunosuppression" result is a mouse study from Dr. Alice Tomei's academic lab at the University of Miami, in fully mismatched murine islet allografts.7 Sernova's own animal work is more sobering: in its allogeneic optimization studies, coated islets in the Cell Pouch achieved normal glucose only in animals also given a single selective immune-response agent — better than a full drug cocktail, but not drug-free.8 The company frames this honestly as an advance over "immunosuppressive cocktails", not as an escape from immunosuppression.8

And it has gone quiet. The last substantive coating updates were in 2023.8 In Sernova's FY2025 Annual Information Form the conformal coating appears only in the patent-portfolio section, as intellectual property; local immune protection is described as something the company is "exploring".9 In the June 2026 quarterly filing, the word does not appear at all.3 There is no IND and no clinical trial for a coated pouch as of July 2026.

So: a real technology, a real patent estate, and a plausible future — but a future. It earns nothing on this record's immunosuppression score, because a goal is not a result.

What would actually change the picture

Two separate problems, two separate fixes, neither one solved:

  • Cell supply. Evotec's iPSC-derived islet-like clusters would replace the scarce deceased-donor pancreas with an off-the-shelf, unlimited source.310 IND-enabling work is ongoing. This fixes supply — it does nothing about the drugs.
  • The drugs. Only the conformal coating (or some other local immune protection) would remove them, and that is preclinical.89

Until the second one lands in a human, the Cell Pouch Bio-hybrid Organ is what its own trial says it is: a better place to put islets, for people who are already going to be on immunosuppression anyway. That is a worthwhile thing to be. It is not a cure without drugs.

One more caveat that belongs on the record: in its June 2026 filing Sernova disclosed material uncertainty casting significant doubt on its ability to continue as a going concern, and stated that Cohort C depends on funding it has not yet secured.3 That is a routine disclosure for a clinical-stage company, not a bankruptcy notice — but timelines here depend on money that does not exist yet.

References

  1. Sernova Biotherapeutics Inc. A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation — detailed description ("immunosuppression is initiated and optimized"), design, eligibility, status (active, not recruiting; n=17; completion Oct 2026). ClinicalTrials.gov, NCT03513939. https://clinicaltrials.gov/study/NCT03513939 ↩ ↩2 ↩3

  2. Pepper AR, Pawlick R, Gala-Lopez B, et al. Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device (prevascularized, retrievable device rationale). Transplantation (2015), via PubMed. https://doi.org/10.1097/TP.0000000000000864 ↩ ↩2

  3. Sernova Biotherapeutics Inc. Management's Discussion and Analysis for the three and six months ended April 30, 2026 (six weeks to establish stable immunosuppression before islet transplant; tegoprubart described as "Eledon's immunosuppressive agent", to be used in place of tacrolimus in Cohort C; Cohort C expected H2 2026 pending additional funding; interim 8/12 insulin-independent; portal-vein top-up; Evotec iPSC programme; going-concern disclosure; no mention of conformal coating). Sernova (June 11, 2026). https://sernova.com/wp-content/uploads/2026/06/Q2_2026_MDA_Final.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  4. Sernova Biotherapeutics. Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes (tegoprubart/AT-1501, anti-CD40L, supplied for Cohort C in place of tacrolimus). Sernova press release (July 9, 2025). https://sernova.com/press_releases/sernova-biotherapeutics-announces-collaboration-with-eledon-pharmaceuticals-to-advance-a-potential-functional-cure-for-type-1-diabetes/ ↩

  5. Sernova Corp. Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function (Cohort A insulin independence; functioning islets recovered from an explanted pouch >5 years post-transplant). Sernova press release (Sep 12, 2024). https://sernova.com/press_releases/sernova-announces-new-positive-data-from-phase-i-ii-trial-regarding-islet-survival-and-function/ ↩ ↩2

  6. Sernova Biotherapeutics. Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes (interim: 8 of 12 insulin-independent; 9 of 12 HbA1c <7.0%; 7 of 12 C-peptide ≥0.3 ng/mL). Sernova press release (May 14, 2025). https://sernova.com/press_releases/sernova-biotherapeutics-provides-positive-interim-data-from-ongoing-phase-1-2-clinical-trial-of-cell-pouch-bio-hybrid-organ-in-patients-living-with-type-1-diabetes/ ↩

  7. Manzoli V, Villa C, Bayer AL, et al. Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol (mouse allografts surviving >100 days without immunosuppression — a murine result). Am J Transplant (2017), via PubMed. https://doi.org/10.1111/ajt.14547 ↩ ↩2 ↩3

  8. Sernova Corp. Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device (preclinical status; syngeneic rat model reversed diabetes; in the allogeneic model, normalized glucose was achieved in subjects "treated with a single selective immune response agent"; GMP coating equipment still being built). Sernova press release (Sep 7, 2023). https://sernova.com/press_releases/sernova-provides-development-update-on-proprietary-cellular-conformal-coating-technology-in-combination-with-cell-pouch-device/ ↩ ↩2 ↩3 ↩4 ↩5

  9. Sernova Biotherapeutics Inc. FY2025 Annual Information Form (conformal coating appears only in the patent-portfolio section; "Local Immune Protection & Other Complementary Technologies" described as being explored; no IND or clinical programme for a coated pouch). Sernova (2026). https://sernova.com/wp-content/uploads/2026/01/FY2025-Annual-Information-Form.pdf ↩ ↩2

  10. Sernova Corp. Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy (off-the-shelf iPSC islet-like clusters to supply the Cell Pouch). GlobeNewswire press release (May 17, 2022). https://www.globenewswire.com/news-release/2022/05/17/2444753/0/en/Sernova-and-Evotec-Enter-into-an-Exclusive-Global-Strategic-Partnership-for-iPSC-Based-Beta-Cell-Replacement-Therapy-to-Develop-and-Commercialize-a-Functional-Cure-for-Diabetes.html ↩

Coming soon

ETA · Phase 1/2 completes October 2026; confirmatory Cohort C expected H2 2026 and contingent on new funding. No approval anywhere; a pivotal programme has not begun.

  • →Cohort C — tacrolimus replaced by tegoprubart (AT-1501), an investigational anti-CD40L antibody. Still chronic systemic immunosuppression, just without a calcineurin inhibitor. · expected H2 2026, contingent on additional funding
  • →IND-enabling work on Evotec's iPSC-derived islet-like clusters in the Cell Pouch — would solve the donor-organ supply problem, not the drug problem.
  • →Per-islet conformal coating (PEG) — the layer that would one day remove anti-rejection drugs. Preclinical; no IND, no trial, and absent from Sernova's June 2026 quarterly disclosure.